Treatment · United States
Active-duty U.S. soldiers to receive psychedelic drugs for PTSD next year
Department of Defense-funded studies will provide MDMA-assisted therapy to active-duty service members with PTSD.
The Guardian reports that two DoD-funded studies will provide MDMA-assisted therapy to 186 active-duty service members with PTSD, the first major active-duty psychedelic therapy program.
The move reframes the post-Lykos psychedelic policy landscape and could shape future FDA submissions if outcomes are favorable.
Read the full Guardian report for the trial design.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.
If reading this brought something up for you —
Call or text 988 for the Suicide & Crisis Lifeline. See all crisis resources.